⚠ COVID-19 INFORMATION: Resources, Vaccine Information

Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology

Brown, P.; Inaba, H.; Annesley, C.; Beck, J.; Colace, S.; Dallas, M.; DeSantes, K.; Kelly, K.; Kitko, C.; Lacayo, N.; Larrier, N.; Maese, L.; Mahadeo, K.; Nanda, R.; Nardi, V.; Rodriguez, V.; Rossoff, J.; Schuettpelz, L.; Silverman, L.; Sun, J.; Sun, W.; Teachey, D.; Wong, V.; Yanik, G.; Johnson-Chilla, A.; Ogba, N.

J Natl Compr Canc Netw. 2020 Jan 8; 18(1):81-112


Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy. Advancements in technology that enhance our understanding of the biology of the disease, risk-adapted therapy, and enhanced supportive care have contributed to improved survival rates. However, additional clinical management is needed to improve outcomes for patients classified as high risk at presentation (eg, T-ALL, infant ALL) and who experience relapse. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for pediatric ALL provide recommendations on the workup, diagnostic evaluation, and treatment of the disease, including guidance on supportive care, hematopoietic stem cell transplantation, and pharmacogenomics. This portion of the NCCN Guidelines focuses on the frontline and relapsed/refractory management of pediatric ALL.

Read More on PubMed